Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects

[1] Blankenberg FG(2012)Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease Mol Genet Metab 107 690-699

[2] Kinsman SL(2017)Transforming lipoxygenases: PE-specific enzymes in disguise Cell 171 501-502

[3] Cohen BH(2015)The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer’s disease Trends Pharmacol Sci 36 181-186

[4] Ye L(2012)Initial experience in the treatment of inherited mitochondrial disease with EPI-743 Mol Genetics Metab 105 91-102

[5] Stockwell B(2017)Therapies for mitochondrial diseases and current clinical trials Mol Genetics Metab 122 1-9

[6] Joshi YB(2018)Double-blind, randomized and controlled trial of EPI-743 in Friedreich’s ataxia Neurodegener Dis Manag 8 233-242

[7] Enns GM(2011)Alpha-tocotrienol quinone modulates oxidative stress response and the biochemistry of aging Bioorg Med Chem Lett 21 3693-3698

[8] El-Hattab AW(2012)EPI-743 reverses the progression of the pediatric mitochondrial disease—genetically defined Leigh syndrome Mol Genetics Metab 107 383-388

[9] Zesiewicz T(2012)Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy Arch Neurol 69 331-338

[10] Shrader WD(2013)Glutathione: a redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies Mol Genet Metab 109 208-214

[1] Blankenberg FG(2012)Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease Mol Genet Metab 107 690-699

[2] Kinsman SL(2017)Transforming lipoxygenases: PE-specific enzymes in disguise Cell 171 501-502

[3] Cohen BH(2015)The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer’s disease Trends Pharmacol Sci 36 181-186

[4] Ye L(2012)Initial experience in the treatment of inherited mitochondrial disease with EPI-743 Mol Genetics Metab 105 91-102

[5] Stockwell B(2017)Therapies for mitochondrial diseases and current clinical trials Mol Genetics Metab 122 1-9

[6] Joshi YB(2018)Double-blind, randomized and controlled trial of EPI-743 in Friedreich’s ataxia Neurodegener Dis Manag 8 233-242

[7] Enns GM(2011)Alpha-tocotrienol quinone modulates oxidative stress response and the biochemistry of aging Bioorg Med Chem Lett 21 3693-3698

[8] El-Hattab AW(2012)EPI-743 reverses the progression of the pediatric mitochondrial disease—genetically defined Leigh syndrome Mol Genetics Metab 107 383-388

[9] Zesiewicz T(2012)Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy Arch Neurol 69 331-338

[10] Shrader WD(2013)Glutathione: a redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies Mol Genet Metab 109 208-214